Broader neutralizing antibodies against H5N1 viruses using prime-boost immunization of hyperglycosylated hemagglutinin DNA and virus-like particles

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Lin, Shih Chang ^a   Lin, Yu Fen ^a   Chong, Pele ^b   Wu, Suh Chin ^a,b  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; IMMUNOGLOBULIN G ANTIBODY; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLADISTICS; CONTROLLED STUDY; CROSS PROTECTION; INFLUENZA VIRUS A H5N1; MALE; MOUSE; NONHUMAN; PROTEIN GLYCOSYLATION; SEQUENCE ALIGNMENT; VIRUS LIKE AGENT;

ANIMALS; ANTIBODIES, NEUTRALIZING; DNA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOSYLATION; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; MICE; MICE, INBRED BALB C; VIRION;

EID: 84862220814     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039075     Document Type: Article

References (41)

1. World Health Organization [WHO] website. Available:http://www.who.int/influenza/resources/documents/h5n1_nomenclature/en/index.html. Accessed 2011 Oct 11.
2. Atmar RL, Keitel WA, (2009) Adjuvants for pandemic influenza vaccines. Curr Top Microbiol Immunol 333: 323-44.
3. Delves PJ, Lund T, Roitt IM, (1997) Can epitope-focused vaccines select advantageous immune responses? Mol Med Today 3: 55-60.
4. Garrity RR, Rimmelzwaan G, Minassian A, Tsai WP, Lin G, et al. (1997) Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. J Immunol 159: 279-89.
5. Chiesa MD, Martensen PM, Simmons C, Porakishvili N, Justesen J, et al. (2001) Refocusing of B-cell responses following a single amino acid substitution in an antigen. Immunology 103: 172-8.
6. Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, et al. (2008) The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microb 6: 143-155.
7. Nara PL, Tobin GJ, Chaudhuri AR, Trujillo JD, Lin G, et al. (2010) How can vaccines against influenza and other viral diseases be made more effective? PLoS Biol 8: e1000571.
8. Zolla-Pazner S, Cardozo T, (2010) Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nat Rev Immunol 10: 527-35.
9. Walker LM, Burton DR, (2010) Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol 22: 358-66.
10. Pantophlet R, Wilson IA, Burton DR, (2003) Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design. J Virol 77: 5889-901.
11. Selvarajah S, Puffer B, Pantophlet R, Law M, Doms RW, et al. (2005) Comparing antigenicity and immunogenicity of engineered gp120. J Virol 79: 12148-63.
12. Selvarajah S, Puffer BA, Lee FH, Zhu P, Li Y, et al. (2008) Focused dampening of antibody response to the immunodominant variable loops by engineered soluble gp140. AIDS Res Hum Retroviruses 24: 301-14.
13. Tobin GJ, Trujillo JD, Bushnell RV, Lin G, Chaudhuri AR, et al. (2008) Deceptive imprinting and immune refocusing in vaccine design. Vaccine 26: 6189-6199.
14. Kutzler MA, Weiner DB, (2008) DNA vaccines: ready for prime time? Nat Rev Genet 9: 776-88.
15. Wang S, Parker C, Taaffe J, Solorzano A, Garcia-Sastre A, et al. (2008) Heterologous HA DNA vaccine prime-inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. Vaccine 26: 3626-33.
16. Ledgerwood JE, Wei CJ, Hu Z, Gordon IJ, Enama ME, et al. (2011) DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis 11(12): 916-24.
17. Suguitan AL, Cheng X, Wang W, Wang S, Jin H, et al. (2011) Influenza H5 hemagglutinin DNA primes the antibody response elicited by the live attenuated influena A/Vietnam/1203/2004 vaccine in ferrets. PLoS One 6: e21942.
18. Lo CY, Wu Z, Misplon JA, Price GE, Pappas C, et al. (2008) Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies. Vaccine 26: 2062-72.
19. Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, et al. (2010) Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 1: e00018-10.
20. Ding H, Tsai C, Gutierrez RA, Zhou F, Buchy P, et al. (2011) Superior neutralizing antibody response and protection in mice vaccinated with heterologous DNA prime and virus like particle boost against HPAI H5N1 virus. PLoS One 6: e16563.
21. Barnett SW, Rajasekar S, Legg H, Doe B, Fuller DH, et al. (1997) Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. Vaccine 15: 869-73.
22. Richmond JF, Lu S, Santoro JC, Weng J, Hu SL, et al. (1998) Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting. J Virol 72: 9092-100.
23. Vaine M, Wang S, Crooks ET, Jiang P, Montefiori DC, et al. (2008) Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination. J Virol 82: 7369-78.
24. Zolla-Pazner S, Cohen SS, Krachmarov C, Wang S, Pinter A, et al. (2008) Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope. Virology 372: 233-46.
25. Zolla-Pazner S, Cohen S, Pinter A, Krachmarov C, Wrin T, et al. (2009) Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope. Virology 392: 82-93.
26. Mizel SB, Honko AN, Moors MA, Smith PS, West AP, (2003) Induction of macrophage nitric oxide production by gram-negative flagellin involves signaling via heteromeric Toll-like receptor 5/Toll-like receptor 4 complexes. J Immunol 170: 6217-6223.
27. Moors MA, Li L, Mizel SB, (2001) Activation of interleukin-1 receptor-associated kinase by gram-negative flagellin. Infect Immun 69: 4424-4429.
28. Wei HJ, Chang W, Lin SC, Liu WC, Chang DK, et al. (2011) Fabrication of influenza virus-like particles using M2 fusion proteins for imaging single viruses and designing vaccines. Vaccine 29: 7163-72.
29. Lin SC, Huang MH, Tsou PC, Huang LM, Chong P, et al. (2011) Recombinant trimeric HA protein immunogenicity of H5N1 avian influenza viruses and their combined use with inactivated or adenovirus vaccines. PLoS One 6: e20052.
30. Huang MH, Lin SC, Hsiao CH, Chao HJ, Yang HR, et al. (2010) Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice. PLoS One 5: e12279.
31. Yang ZY, Wei CJ, Kong WP, Wu L, Xu L, et al. (2007) Immunization by avian H5 influenza hemagglutinin mutants with altered receptor binding specificity. Science 317: 825-8.
32. Yang H, Chen LM, Carney PJ, Donis RO, Stevens J, (2010) Structures of receptor complexes of a North American H7N2 influenza hemagglutinin with a loop deletion in the receptor binding site. PLoS Pathog 6: e1001081.
33. World Health Organization [WHO] website. Available:http://www.who.int/influenza/resources/documents/2011_09_h5_h9_vaccinevirusupdate.pdf. Accessed 2011 Oct 11.
34. Gerhard W, Yewdell J, Frankel ME, Webster R, (1981) Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies. Nature 290: 713-7.
35. Caton AJ, Brownlee GG, Yewdell JW, Gerhard W, (1982) The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 31: 417-27.
36. Sui J, Hwang WC, Perez S, Wei G, Aird D, et al. (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16: 265-73.
37. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, et al. (2011) A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333: 850-6.
38. Krause JC, Tsibane T, Tumpey TM, Huffman CJ, Basler CF, et al. (2011) A Broadly Neutralizing Human Monoclonal Antibody That Recognizes a Conserved, Novel Epitope on the Globular Head of the Influenza H1N1 Virus Hemagglutinin. J Virol 85: 10905-8.
39. Whittle JR, Zhang R, Khurana S, King LR, Manischewitz J, et al. (2011) Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci U S A 108: 14216-21.
40. Ohshima N, Iba Y, Kubota-Koketsu R, Asano Y, Okuno Y, et al. (2011) Naturally occurring antibodies in humans can neutralize a variety of influenza virus strains, including h3, h1, h2, and h5. J Virol 85: 11048-57.
41. Kwong PD, Wilson IA, (2009) HIV-1 and influenza antibodies: seeing antigens in new ways. Nat Immunol 10: 573-8.